New Price‑Control Rule Cuts Cancer Medicine Prices Up to 70 %
The Ministry of Chemicals and Fertilizers announced a stringent limit on trade margins for oncology drugs that are not part of the scheduled list. By restricting the margin to 30 % of the MRP, the government anticipates that the retail price of several high‑cost cancer medicines could drop by as much as 70 %.
If the projection holds, Indian cancer patients could collectively save about ₹2,500 crore each year. The move follows longstanding complaints from state health officials, patient advocacy groups and NGOs about wide gaps between purchase prices for manufacturers and the final selling price to consumers.
The DGHS‑led expert panel will identify the specific medicines to be included, after which the NPPA will publish the definitive regulation. The policy covers both branded and generic versions, domestic and imported products, and patented as well as non‑patented formulations, ensuring that supply is not compromised while prices become more affordable.
Historical data from a similar 2019 initiative, which capped margins on 42 non‑scheduled cancer drugs, showed a 91 % reduction in maximum retail prices for certain products, saving the market roughly ₹984 crore annually. Building on that success, the current rule expands the coverage to a much larger pool of medicines.